Abstract
Objective: The membrane complement regulatory protein, CD55, drives chemoresistance in endometrioid carcinoma cells by activating LCK (lymphocyte-specific protein tyrosine kinase). This study sought to test LCK inhibitors as chemosensitizing agents for platinum-resistant endometrioid carcinoma cells.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
